Liverty TIPS Stent Graft
Bard Peripheral Vascular, Inc. · Decision date Oct 23, 2026
What did the FDA decide?
FDA posted a 30-day notice for P250050/S001, dated October 23, 2026, with decision OK30. The supplement concerns a modification to the manufacturing process of the inner ePTFE covering material of the Bard Liverty TIPS Stent Graft. The applicant is Bard Peripheral Vascular, Inc., and the supplement type is a process change involving manufacturer, sterilizer, packager, or supplier.
The device is classified as a shunt, portosystemic, endoprosthesis under product code MIR in the cardiovascular specialty. The source statement does not describe the specific process change, the reason for the modification, or any resulting labeling or performance changes. This notice is not a new approval of the whole system and does not establish a new indication or independent proof of safety or clinical effectiveness.
FDA approval order statement
modification to the manufacturing process of the inner ePTFE covering material of the Bard Liverty TIPS Stent Graft
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250050/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- MIR
- Decision code
- OK30
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS.
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- MIR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250050. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250050 · Original PMA
Liverty TIPS Stent Graft
P250050/S001 received
Application receipt date recorded by FDA.
P250050/S001 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P250050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250050
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Liverty TIPS Stent GraftP250050 | Bard Peripheral Vascular, Inc. | PMA approval | Sep 25, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bard Peripheral Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1625 W. 3rd St., Tempe, AZ, 85281
Sources and methodology
- Original FDA record: P250050/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records